Imatinib alone and in combination for chronic myeloid leukemia

Schematic of point mutations in the Abl kinase domain. The Abl kinase domain, from amino acid 240 to 500, is shown with the adenosine triphosphate (ATP) binding domain (P), the catalytic domain (C), and the activation loop (A). Numbers below the kinase domain designate amino acids that are mutated in patients who relapsed on therapy with imatinib. Vertical lines above the kinase domain indicate the number of times each amino acid has been found to be mutated, as compiled from several sources. (Adapted from Shah et al,⁴⁴ with permission of Elsevier Science.)